Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice

Neuropsychopharmacology

Volumn 32, Issue 4, 2007, Pages 822-834

  Billes, Sonja K ^a   Cowley, Michael A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antidepressant; Body weight; Bupropion; Food intake; Obesity; Reuptake inhibitor

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; AMFEBUTAMONE; DOPAMINE; NISOXETINE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CATECHOLAMINE NERVE CELL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENTIATION; ENERGY BALANCE; FOOD INTAKE; LEAN BODY WEIGHT; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOTYPY; WEIGHT REDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BUPROPION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EATING; ENERGY METABOLISM; FLUOXETINE; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; OBESITY; PIPERAZINES; TIME FACTORS;

EID: 33947232740     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301155     Document Type: Article

References (50)

1. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM (2002). Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10: 633-641.
2. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC et al (1995). Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56: 395-401.
3. Bina KG, Cincotta AH (2000). Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 71: 68-78.
4. Bondarev ML, Bondareva TS, Young R, Glennon RA (2003). Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474: 85-93.
5. Bonnet JJ, Costentin J (1986). GBR 12783, a potent and selective inhibitor of dopamine uptake: biochemical studies in vivo and ex vivo. Eur J Pharmacol 121: 199-209.
6. 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 35: 63-70.
7. Cone RD (2005). Anatomy and regulation of the central melanocortin system. Nat Neurosci 8: 571-578.
8. Cooper SJ, van der Hoek GA (1993). Cocaine: a microstructural analysis of its effects on feeding and associated behaviour in the rat. Brain Res 608: 45-51.
9. Davidson J (1989). Seizures and bupropion: a review. J Clin Psychiatry 50: 256-261.
10. Eisenhofer G (2001). The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91: 35-62.
11. Fetissov SO, Meguid MM, Sato T, Zhang LH (2002). Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am J Physiol Regul Integr Comp Physiol 283: R905-R910.
12. Gadde KM, Parker CB, Maner LG, Wagner II HR, Logue EJ, Drezner MK et al (2001). Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 9: 544-551.
13. Halford JC (2006). Pharmacotherapy for obesity. Appetite 46: 6-10.
14. Harto-Truax N, Stern WC, Miller LL, Sato TL, Cato AE (1983). Effects of bupropion on body weight. J Clin Psychiatry 44: 183-186.
15. Hasegawa H, Meeusen R, Sarre S, Diltoer M, Piacentini MF, Michotte Y (2005). Acute dopamine/noradrenaline reuptake inhibition increases brain and core temperature in rats. J Appl Physiol 99: 1397-1401.
16. Hoffman BB (2001). Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Goodman Gilman A (eds). Goodman & Gilman's The Pharmacological Bases of Therapeutics. McGraw-Hill: New York. pp 215-268.
17. Horvath TL (2005). The hardship of obesity: a soft-wired hypothalamus. Nat Neurosci 8: 561-565.
18. Huang XF, Yu Y, Zavitsanou K, Han M, Storlien L (2005). Differential expression of dopamine D2 and D4 receptor and tyrosine hydroxylase mRNA in mice prone, or resistant, to chronic high-fat diet-induced obesity. Brain Res Mol Brain Res 135: 150-161.
19. Hughes JR, Stead LF, Lancaster T (2004). Antidepressants for smoking cessation. Cochrane Database Syst Rev: CD000031.pub2. DOI:10.1002/14651858.CD000031.pub2.
20. Inenaga K, Dyball RE, Okuya S, Yamashita H (1986). Characterization of hypothalamic noradrenaline receptors in the supraoptic nucleus and periventricular region of the paraventricular nucleus of mice in vitro. Brain Res 369: 37-47.
21. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ (1997). Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 121: 1613-1618.
22. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER et al (2002). Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 10: 1049-1056.
23. Kaya A, Aydin N, Topsever P, Filiz M, Ozturk A, Dagar A et al (2004). Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 58: 582-587.
24. Levin BE, Triscari J, Sullivan AC (1986). The effect of diet and chronic obesity on brain catecholamine turnover in the rat. Pharmacol Biochem Behav 24: 299-304.
25. Lin S, Thomas TC, Storlien LH, Huang XF (2000). Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 24: 639-646.
26. Liu YL, Connoley IP, Heal DJ, Stock MJ (2004). Pharmacological characterisation of the thermogenic effect of bupropion. Eur J Pharmacol 498: 219-225.
27. Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ (1990). Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23: 187-194.
28. Millan MJ, Lejeune F, Gobert A (2000). Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14: 114-138.
29. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1992). Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7: 7-14.
30. Paladini CA, Robinson S, Morikawa H, Williams JT, Palmiter RD (2003). Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism. Proc Natl Acad Sci USA 100: 2866-2871.
31. Paladini CA, Williams JT (2004). Noradrenergic inhibition of midbrain dopamine neurons. J Neurosci 24: 4568-4575.
32. Pelletier G, Simard J (1991). Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus. Neurosci Lett 127: 96-98.
33. Rowland NE, Lo J, Robertson K (2001). Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol. Psychopharmacology (Berlin) 157: 193-196.
34. Saper CB, Chou TC, Elmquist JK (2002). The need to feed: homeostatic and hedonic control of eating. Neuron 36: 199-211.
35. Scates AC, Doraiswamy PM (2000). Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 34: 1302-1312.
36. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA (1999). Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 21: 454-463.
37. Simpson D, Plosker GL (2004). Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64: 205-222.
38. Slinker BK (1998). The statistics of synergism. J Mol Cell Cardiol 30: 723-731.
39. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004). A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 6: 159-166.
40. Tallarida RJ (2001). Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872.
41. Thomas SA, Palmiter RD (1997). Disruption of the dopamine betahydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. Behav Neurosci 111: 579-589.
42. Tong Y, Pelletier G (1992). Role of dopamine in the regulation of proopiomelanocortin (POMC) mRNA levels in the arcuate nucleus and pituitary gland of the female rat as studied by in situ hybridization. Brain Res Mol Brain Res 15: 27-32.
43. Wang GJ, Volkow ND, Fowler JS (2002). The role of dopamine in motivation for food in humans: implications for obesity. Expert Opin Ther Targets 6: 601-609.
44. Welch RM, Lai AA, Schroeder DH (1987). Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 17: 287-298.
45. Wellman PJ (2005). Modulation of eating by central catecholamine systems. Curr Drug Targets 6: 191-199.
46. Wessinger WD (1986). Approaches to the study of drug interactions in behavioral pharmacology. Neurosci Biobehav Rev 10: 103-113.
47. Wise RA (2004). Dopamine, learning and motivation. Nat Rev Neurosci 5: 483-494.
48. Yang ZJ, Meguid MM, Chai JK, Chen C, Oler A (1997). Bilateral hypothalamic dopamine infusion in male Zucker rat suppresses feeding due to reduced meal size. Pharmacol Biochem Behav 58: 631-635.
49. Zarrindast MR, Hosseini-Nia T (1988). Anorectic and behavioural effects of bupropion. Gen Pharmacol 19: 201-204.
50. Zhou QY, Palmiter RD (1995). Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83: 1197-1209.